FIELD: chemistry.
SUBSTANCE: invention relates to biotechnology and specifically to an isolated antibody or antigen-binding fragment thereof, which specifically binds β-amyloid derived diffusible ligands, as well as to the use thereof. Said antibody or fragment thereof comprises a light chain variable region comprising CDR1 with SEQ ID NO:1, CDR2 with SEQ ID NO:2, CDR3 with SEQ ID NO:10; and a heavy chain variable region comprising CDR1 with SEQ ID NO:4, CDR2 with SEQ ID NO:5, and CDR3 with SEQ ID NO:6. The antibodies are selective with respect to ADDL, can penetrate the brain and are useful in methods of detecting ADDL and diagnosing Alzheimer's disease. The antibodies also block the binding of ADDL with neurons, ADDL assembling and phosphorylation of tau-protein.
EFFECT: present invention enables to specifically bind β-amyloid derived diffusible ligands.
11 cl, 19 dwg, 8 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| AGENTS, APPLICATION WAYS AND METHODS FOR TREATING SYNUCLEOPATHY | 2016 |
|
RU2765303C2 |
| PHARMACEUTICAL COMPOSITION | 2011 |
|
RU2603078C2 |
| METHODS AND REAGENTS FOR IMPROVEMENT OF DETECTING AMYLOID BETA-PEPTIDES | 2010 |
|
RU2554774C2 |
| PHOSPHO-SPECIFIC ANTIBODIES RECOGNIZING TAU | 2012 |
|
RU2639537C2 |
| ANTIBODIES WHICH BIND TO SORTILIN AND INHIBIT THE BINDING OF PROGRANULIN | 2016 |
|
RU2735639C2 |
| HUMANISED ANTIBODIES TO β-AMYLOID PEPTIDE | 2008 |
|
RU2475500C2 |
| ANTIBODIES | 2018 |
|
RU2798399C2 |
| ANTIBODY, WHICH RECOGNIZES PEPTIDE T14 ACHE | 2016 |
|
RU2729491C2 |
| PREVENTION AND TREATMENT OF CEREBRAL AMYLOID ANGIOPATHY | 2008 |
|
RU2523894C2 |
| BCMA HEAVY CHAIN ANTIBODIES | 2018 |
|
RU2816994C2 |
